Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy

Overview

To determine the optimal time for the Tenofovir treatment of anti-Hepatitis B Virus (HBV) during the pregnancy among women with chronic HBV infection and high HBV DNA load. This is a randomized, open-label, three-arms, parallel-controlled clinical trial. Pregnant women with high HBV load and normal liver function will be treated with tenofovir during the middle or late stage of pregnancy, started from 24th gestational week, 28th gestational week and 32th gestational week through 1 month postpartum, respectively. The HBV DNA load at 40th gestational week of mothers, the intrauterine HBV infection rate of infants will be compared across the three groups.

Full Title of Study: “An Open-label, Randomized, Controlled Clinical Trial to Determine the Optimal Time for Tenofovir of Anti-HBV Treatment During the Pregnancy Among Chronic HBV-infected Pregnant Women With Normal Liver Function”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2017

Detailed Description

Tenofovir Disoproxil Fumarate is a American Food and Drug Administration (FDA) pregnancy class B drug. To determine the optimal time for the tenofovir treatment during the pregnancy among women with chronic HBV infection and high HBV DNA load. Pregnant women with high HBV DNA load and normal liver function at second trimester will be randomized into three treatment groups at the 20th week of gestation and treated with tenofovir from 24 weeks, 28 weeks and 32 weeks to 1 month postpartum, respectively. The blood will be drawn at 24 weeks, 28 weeks, 32 weeks, 36 weeks and the delivery, respectively and the HBV DNA load and liver functions will be tested. The status of HBV infection for infants will be observed at 1st month, 7th month and 12th month after the babies were delivered. The HBV DNA load at 40th gestational week of mothers, the intrauterine HBV infection rate of infants and safety outcomes will be compared across the three groups.

Interventions

  • Drug: Tenofovir Disoproxil Fumarate
    • Use Tenofovir at 24week of gestation
  • Drug: Tenofovir Disoproxil Fumarate
    • Use Tenofovir at 28week of gestation
  • Drug: Tenofovir Disoproxil Fumarate
    • Use Tenofovir at 32week of gestation

Arms, Groups and Cohorts

  • Experimental: Tenofovir 24 week
    • Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
  • Experimental: Tenofovir 28 week
    • Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
  • Active Comparator: Tenofovir 32 week
    • Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum

Clinical Trial Outcome Measures

Primary Measures

  • HBV DNA load in serum
    • Time Frame: 40 weeks, from randomization to delivery
    • the difference in the percentage of mothers whose HBV DNA load in serum are less than 10*2 IU/ml at delivery among the groups

Secondary Measures

  • Intrauterine HBV infection rate of infants
    • Time Frame: 12 months, from delivery to one-year birth date
    • Intrauterine HBV infection rate of infants at the 12th months after delivery
  • Change in HBV DNA load
    • Time Frame: 40 weeks, from randomization to delivery
    • Total change in HBV DNA load from the start of treatment to the delivery was compared across the three groups
  • Change in hepatitis B e antigen (HBeAg) titer
    • Time Frame: 40 weeks, from randomization to delivery
    • Total change in HBeAg titer from the start of treatment to the delivery was compared across the three groups

Participating in This Clinical Trial

Inclusion Criteria

  • Women between 20 and 40 years old – Have had HBsAg positive in serum greater than 6 months – HBV DNA load>10**6 IU/ml – Gestation week<24 weeks – Normal liver function – Able to comprehend and willing to sign the informed consent form Exclusion Criteria:

  • Combined with following infections: hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV) and human immunodeficiency virus (HIV) – Got antiviral treatments before 24 weeks of Gestation – Got immunosuppressor treatment and/or steroids – Got diagnosis of cirrhosis,hepatocellular carcinoma or severe hepatitis B – Got serious obstetric complications – Got evidence of fetal deformity diagnosed by four-dimensional color Doppler ultrasound examination – Biological father of infant had HBV infection

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • First Affiliated Hospital Xi’an Jiaotong University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tianyan Chen, MD,PHD, Principal Investigator, First Affiliated Hospital Xi’an Jiaotong University
  • Overall Contact(s)
    • Jinfeng Liu, MB, +86-13259927840, prettycaofurong@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.